Drug intelligence / Profile preview

N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide

Development stage: Unknown
Modality: Small Molecules

Overview

N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide is a synthetic small molecule belonging to the benzamide class, characterized by a cyclopropyl-substituted pyrazole ring linked to a benzamide moiety. It has been studied primarily as a research tool and chemical probe rather than as an approved pharmaceutical agent. The compound is known to act as an inhibitor of cyclin-dependent kinase 2 (CDK2), with reported in vitro activity (IC50 ≈ 290 nM). CDK2 is involved in cell cycle regulation, making this compound of interest for cancer biology and cell cycle research. There are no known clinical indications or marketed formulations for this molecule[1][2][3].

Other names: N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide.

Explore the full profile